Drilldown: Medicines

Escitalopram (1) · Finasteride (1) · Linagliptin (1)

Lexapro (1) · Proscar (5 mg, BPH), Propecia (1 mg, alopecia) (1) · Tradjenta; with metformin Jentadueto (1)

[[:Category:5-alpha-reductase_inhibitors|5α-reductase inhibitor]] (1) · [[:Category:Androgen_modulators|Androgen modulator]] (1) · [[:Category:Antidepressants|Antidepressant]] (1) · [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) · [[:Category:Anxiolytics|Anxiolytic]] (1) · [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (1) · [[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (1) · [[:Category:Incretin_modulators|Incretin pathway modulator]] (1) · [[:Category:SSRIs|Selective serotonin reuptake inhibitor (SSRI)]] (1)

None (2) · '"`UNIQ--vote-0000001D-QINU`"' CYP2C19 + CYP3A4 metabolism, with CPIC PGx guidance: poor CYP2C19 metabolizers have ~3-fold higher exposure and benefit from a lower starting dose; ultrarapid metabolizers may have inadequate response'"`UNIQ--ref-0000001E-QINU`"'. (1)

'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1) · '"`UNIQ--vote-0000052E-QINU`"', '"`UNIQ--vote-0000052F-QINU`"', '"`UNIQ--vote-00000530-QINU`"' (1) · '"`UNIQ--vote-0000117B-QINU`"' (1)

10 mg PO once daily; titrate to 20 mg/day after 1-2 weeks if needed (1) · 5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia (1) · 5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1)

1 mg, 5 mg tablets (1) · 5 mg tablets; combination with metformin (1) · Tablets 5, 10, 20 mg; oral solution 1 mg/mL (1)

None · Indication-specific · 40 mg/d · 10 mg/d · 20 mg/d · 80 mg/d · 10 mg/d (adults) · 100 mg/d · 4 g/d · 400 mg/d · 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison · 5 mg/d · 50 mg/d · 600 mg/d · No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals · No fixed maximum; titrated to TSH target · TID per eye · Titrated to glucose; no fixed ceiling · Titrated to glucose; no fixed maximum · '''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60

Other values:

Search

None · Oral · IV · Topical · IM · intranasal · rectal · Subcutaneous · Topical ophthalmic · ophthalmic · intramuscular · intravenous · transdermal · vaginal · Subcutaneous (abdomen · sublingual · thigh · Inhaled · SC · intra-articular

Other values:

Search

Antidepressant effect emerges over 1-2 weeks; full clinical effect 4-6 weeks (1) · BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months (1) · Postprandial glucose effect within days; HbA1c by 12 weeks (1)

24 hours (2) · 24 hours (once-daily dosing) (1)

27-32 hours'"`UNIQ--ref-00000026-QINU`"' (1) · ~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) · ~5-6 hours in young men, ~8 hours in elderly'"`UNIQ--ref-00000531-QINU`"' (1)

~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) · ~63% (oral)'"`UNIQ--ref-00000532-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-00000027-QINU`"' (1)

None (1) · '''Pregnant individuals should not handle crushed/broken tablets''' (skin absorption risk); can cause hypospadias in male fetus. Not used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

[[USLegal:Prescription only|Rx-only]] in US (2) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000028-QINU`"' (1)